IXJ
HealthcareiShares Global Healthcare ETF
iShares · Tracks S&P Global 1200 Healthcare Sector Index · Inception Nov 13, 2001
Composite score
Based on a 0.40% expense ratio.
Based on $3.84B in net assets.
Top-10 holdings represent 45.8% of net assets.
Healthcare base · ETF wrapper · 1.47% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use IXJ in our tools
Tool · Cost
Compare IXJ's fee against another fund
Compounds the 0.40% expense ratio against a peer over decades.
Tool · Overlap
Compare IXJ's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar Healthcare funds.
Tool · TLH
Find a tax-loss harvesting partner for IXJ
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | ELI LILLY AND COMPANY | 9.44% |
| 2 | JOHNSON & JOHNSON | 7.63% |
| 3 | ABBVIE INC. | 4.98% |
| 4 | ASTRAZENECA PLC | 4.02% |
| 5 | MERCK & CO., INC. | 3.96% |
| 6 | Novartis AG | 3.87% |
| 7 | Roche Holding AG | 3.72% |
| 8 | UNITEDHEALTH GROUP INCORPORATED | 3.25% |
| 9 | AMGEN INC. | 2.51% |
| 10 | THERMO FISHER SCIENTIFIC INCORPORATED | 2.45% |
Compare IXJ with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open IXJ at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.